{"groups":[{"description":"Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle","id":"FG000","title":"Belantamab Mafodotin"},{"description":"Participants with RRMM received 4 mg pomalidomide capsule daily on Days 1 to 21 of each 28-day cycle, along with 40 mg or at lower 20 mg (for participants \\>75 years of age) dose of dexamethasone tablet once weekly (Days 1, 8, 15 and 22)","id":"FG001","title":"Pomalidomide Plus Dexamethasone"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"51"},{"groupId":"FG001","numSubjects":"26"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"9"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"3"}],"type":"Ongoing at the time of analysis"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"218"},{"groupId":"FG001","numSubjects":"107"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"217"},{"groupId":"FG001","numSubjects":"102"}],"comment":"All randomized participants who took at least 1 dose of study intervention","type":"Safety Population"},{"achievements":[{"groupId":"FG000","numSubjects":"126"},{"groupId":"FG001","numSubjects":"68"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"92"},{"groupId":"FG001","numSubjects":"39"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"The results presented are based on the data cut-off date of 22 April 2025. Those participants still benefiting from study drug in the opinion of their treating physician continue to receive study drug in Post Analysis Continued Treatment (PACT) phase and their safety data will be reported after they stop receiving treatment as per protocol"}